{"contentid": 488610, "importid": NaN, "name": "Merck KGaA confirms positive quarter and promises \u00e2\u0080\u0098sustainable growth\u00e2\u0080\u0099", "introduction": "Germany\u00e2\u0080\u0099s Merck KGaA confirmed what investors already knew by posting positive first quarter 2021 financial results on Wednesday.", "content": "<p>Germany&rsquo;s Merck KGaA (MRK: DE) confirmed what investors already knew by posting positive first quarter 2021 financial results on Wednesday.</p>\n<p>The company announced last week, prior to the full results presentation, that it was raising its full-year forecast based on high demand expected to continue throughout 2021 and a very strong first quarter.</p>\n<p>Net sales of 4.63 billion euros ($5.59 billion) resulted in earnings before interest, taxes, depreciation and amortization (EBITDA) pre of 1.51 billion euros and earnings per share (EPS) pre of 2.18 euros.</p>\n<p>The sales figure was a rise of 6% on last year, while EBITDA-pre jumped by nearly 28% and exceeded expectations.</p>\n<h2>'Strength in a challenging environment'</h2>\n<p>Merck now projects net sales of around 18.5 to 19.5 billion euros for 2021 as a whole. EBITDA pre is anticipated to grow to around 5.4 to 5.8 billion euros. Both represent an increase on previous guidance.</p>\n<p>Shares in Merck were down by nearly 2% as markets edged towards closing on Wednesday, with the results not having provided that much new on top of what was said last week.</p>\n<p>Bel&eacute;n Garijo, chairman of the executive board and chief executive of Merck, said: &ldquo;In the first quarter, we demonstrated great strength in a challenging market environment. Our businesses are shaping the future of science and technology in high-growth markets.</p>\n<p>\"This company is poised for sustainable growth, and we will continue to deliver outstanding results for patients, researchers and customers worldwide.&rdquo;</p>\n<h2><strong>Pharmaceutical product sales</strong></h2>\n<p>Erbitux (cetuximab): 219 million euros, up 4%</p>\n<p>Bavencio (avelumab): 62 million euros, up 89%</p>\n<p>Rebif (interferon beta-1a): 227 million euros, down 23%</p>\n<p>Mavenclad (cladribine): 147 million euros, up 19%</p>\n<p>Glucophage (metformin): 217 million, down 7%</p>", "date": "2021-05-12 15:05:00", "meta_title": NaN, "meta_keywords": NaN, "meta_description": NaN, "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-12 14:52:48", "updated": "2021-05-12 15:51:06", "access": NaN, "url": "https://www.thepharmaletter.com/article/merck-kgaa-confirms-positive-quarter-and-promises-sustainable-growth", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "merckkgaa-big.png", "image2id": "merckkgaanewsmall.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Diabetes, Oncology", "topic_tag": "Financial, Management", "geography_tag": "Germany", "company_tag": "Merck KGaA", "drug_tag": "Bavencio, Erbitux, Glucophage, Mavenclad, Rebif", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-12 15:05:00"}